Human papillomavirus screening: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
Line 6: Line 6:


==Screening==
==Screening==
High-risk [[Human papillomavirus|HPV]] types are associated with 70% of [[Cervical cancer|cervical cancers]] in females having persistent infection.<ref name=CDC4>http://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html#epi Accessed on October 13, 2016</ref> Due to this strong association between [[Human papillomavirus|HPV]] and [[cervical cancer]], [[cervical cancer]] screening is recommended in all females from age 21. According to the [[US Preventive Services Task Force]] (USPSTF), specific screening guidelines for cervical cancer is described below:<ref name="pmid22711081">{{cite journal| author=Moyer VA, U.S. Preventive Services Task Force| title=Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. | journal=Ann Intern Med | year= 2012 | volume= 156 | issue= 12 | pages= 880-91, W312 | pmid=22711081 | doi=10.7326/0003-4819-156-12-201206190-00424 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22711081  }} </ref><ref name="pmid25302174">{{cite journal| author=McGraw SL, Ferrante JM| title=Update on prevention and screening of cervical cancer. | journal=World J Clin Oncol | year= 2014 | volume= 5 | issue= 4 | pages= 744-52 | pmid=25302174 | doi=10.5306/wjco.v5.i4.744 | pmc=4129537 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25302174  }} </ref>
High-risk [[Human papillomavirus|HPV]] types are associated with 70% of [[Cervical cancer|cervical cancers]] in females having persistent infection.<ref name=CDC4>http://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html#epi Accessed on October 13, 2016</ref> Due to this strong association between [[Human papillomavirus|HPV]] and [[cervical cancer]], [[cervical cancer]] screening is recommended in all females from age 21. According to the [[US Preventive Services Task Force]] (USPSTF), specific screening guidelines for cervical cancer is described below:<ref name="pmid22711081">{{cite journal| author=Moyer VA, U.S. Preventive Services Task Force| title=Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. | journal=Ann Intern Med | year= 2012 | volume= 156 | issue= 12 | pages= 880-91, W312 | pmid=22711081 | doi=10.7326/0003-4819-156-12-201206190-00424 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22711081  }} </ref><ref name="pmid25302174">{{cite journal| author=McGraw SL, Ferrante JM| title=Update on prevention and screening of cervical cancer. | journal=World J Clin Oncol | year= 2014 | volume= 5 | issue= 4 | pages= 744-52 | pmid=25302174 | doi=10.5306/wjco.v5.i4.744 | pmc=4129537 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25302174 }} </ref><ref name="pmid34292926">{{cite journal| author=Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I | display-authors=etal| title=Sexually Transmitted Infections Treatment Guidelines, 2021. | journal=MMWR Recomm Rep | year= 2021 | volume= 70 | issue= 4 | pages= 1-187 | pmid=34292926 | doi=10.15585/mmwr.rr7004a1 | pmc=8344968 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34292926 }} </ref>


{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center

Latest revision as of 01:48, 9 September 2021

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]

Sexually transmitted diseases Main Page

Human papillomavirus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Human papillomavirus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Human papillomavirus screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Human papillomavirus screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Human papillomavirus screening

CDC on Human papillomavirus screening

Human papillomavirus screening in the news

Blogs on Human papillomavirus screening

Directions to Hospitals Treating Human papillomavirus

Risk calculators and risk factors for Human papillomavirus screening

Overview

High-risk HPV types are associated with 70% of cervical cancers in females having persistent infection.[1] Due to this strong association between HPV and cervical cancer, cervical cancer screening is recommended in all females from age 21. According to the US Preventive Services Task Force (USPSTF), specific screening guidelines for cervical cancer includes screening all females from age 21 to 65 for cervical cancer.[2][3]

Screening

High-risk HPV types are associated with 70% of cervical cancers in females having persistent infection.[1] Due to this strong association between HPV and cervical cancer, cervical cancer screening is recommended in all females from age 21. According to the US Preventive Services Task Force (USPSTF), specific screening guidelines for cervical cancer is described below:[2][3][4]

Population Recommendations
Women 21 to 65 (pap Smear)
Women aged 30-65
Women younger than 21
Women older than 65 (who have had adequate prior screening)
Women after hysterectomy with removal of cervix (no h/o high grade precancer or cervical cancer)
Women before age 30

References

  1. ↑ 1.0 1.1 http://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html#epi Accessed on October 13, 2016
  2. ↑ 2.0 2.1 Moyer VA, U.S. Preventive Services Task Force (2012). "Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement". Ann Intern Med. 156 (12): 880–91, W312. doi:10.7326/0003-4819-156-12-201206190-00424. PMID 22711081.
  3. ↑ 3.0 3.1 McGraw SL, Ferrante JM (2014). "Update on prevention and screening of cervical cancer". World J Clin Oncol. 5 (4): 744–52. doi:10.5306/wjco.v5.i4.744. PMC 4129537. PMID 25302174.
  4. ↑ Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I; et al. (2021). "Sexually Transmitted Infections Treatment Guidelines, 2021". MMWR Recomm Rep. 70 (4): 1–187. doi:10.15585/mmwr.rr7004a1. PMC 8344968 Check |pmc= value (help). PMID 34292926 Check |pmid= value (help).
  5. ↑ Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T; et al. (2008). "Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005". Ann Intern Med. 148 (7): 493–500. PMID 18378945 PMID: 18378945 Check |pmid= value (help).


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Human_papillomavirus_screening&oldid=1713326"